Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter establishes $200M VC fund

This article was originally published in Scrip

Executive Summary

Baxter International has become the latest healthcare multinational to establish its own venture capital fund. The company has announced plans to create Baxter Ventures to invest up to $200 million in promising early stage companies developing therapies that complement Baxter's existing portfolio. With many traditional venture capital houses moving away from early stage drug discovery and development investing, an increasing number of pharmaceutical companies are creating their own corporate venture arms to fill the innovation investment vacuum.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC013875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel